Furthermore, Mosele and colleagues recently reported that patients with PIK3CA-mutated metastatic tumors presented with a poor prognosis and resistance to chemotherapy in hormone receptor-positive, HER2-negative metastatic breast cancer34. This evidence concerns the gene NR4A1 and metastatic neoplasm.